An Indiana University Melvin and Bren Simon Comprehensive Cancer Center researcher has been awarded a five-year, $2.9 million grant from the National Cancer Institute to develop a drug that could make radiation therapy far more effective.
Researchers at Washington University School of Medicine in St. Louis have completed a clinical trial suggesting that the antidepressant drug fluvoxamine may help prevent deterioration in COVID-19 patients, making hospitalization less likely.
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) .
Analysis update by the nonprofit Cancer Research Institute reveals dramatic growth in PD-1/PD-L1 monoclonal antibody combination cancer treatment strategies in global clinical trial pipeline
The ongoing global pandemic has created an urgent need for rapid tests that can diagnose the presence of the SARS-CoV-2 virus, the pathogen that causes COVID-19, and distinguish it from other respiratory viruses.
Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis
Both fatal and nonfatal overdoses have increased this year compared to last, according to a recent report by the Overdose Data Mapping Application Program. And, anecdotal information suggests that compared to last year, people in recovery are relapsing at alarming rates.
The high price of prescription drugs is an important issue for voters, and in the past 50 years, Congress and the president have made little headway in restraining costs.
A wave of new studies shows what happens when surgical teams work together to reduce the emphasis on, and supply of, opioid painkillers while still seeking to ease surgery patients’ pain.
Biogen tried, and failed, to win FDA committee approval for its anti-amyloid Alzheimer's drug. The Alzheimer's Association supported the application but did not reveal significant monies received from the firm.
A novel drug called vamorolone may improve the efficacy of corticosteroid treatment for patients with Duchenne muscular dystrophy — a rare form of inherited and progressive muscular dystrophy, according findings from a clinical trial published in the journal PLOS Medicine.
New insights into the way the body distributes dexamethasone could mean that patients with high blood sugar may see diminished effects.
At a glance: • Receipt of antibiotics for acute respiratory infections makes it more likely that patients and their families will seek care and receive antibiotics for future respiratory viral infections. • Antibiotics work against bacteria but not against viruses, and improper use can make bacteria resistant to these drugs. • The analysis reveals concerning variations in the prescribing patterns of urgent care clinicians. • In the year after their visit, patients randomly assigned to clinicians who prescribed more antibiotics got 15 percent more antibiotics for viral respiratory infections compared with patients seen by clinicians who prescribed the fewest antibiotics. • The findings underscore the importance of judicious antibiotic prescribing only for infections that can benefit from antibiotic therapy.
Findings from a national study published today in the Journal of the American Medical Association (JAMA) “do not support” the use of hydroxychloroquine for the treatment of adult patients hospitalized with COVID-19.
The use of antipsychotics in young children is declining but doctors continue to prescribe these medications off-label for conditions not approved by the Food and Drug Administration and without the recommended psychiatric consultation, a Rutgers study found.
A study from investigators at Hospital for Special Surgery (HSS) and Brigham and Women’s Hospital in Boston has found that the synovial fluid and blood of people experiencing checkpoint inhibitor-induced arthritis is populated by a type of T cells rarely seen in people with other types of inflammatory arthritis. The findings are being presented at the virtual American College of Rheumatology annual meeting.
Researchers from the Universities of Melbourne, York, Warwick and Oxford have shed light on how encapsulated viruses like hepatitis B, dengue and SARS-CoV-2 hijack the protein manufacturing and distribution pathways in the cell - they have also identified a potential broad spectrum anti-viral drug target to stop them in their tracks.
UCLA Health has helped drive monumental advances in the treatment of lung cancer – increasing survival rates in the nation’s leading cause of cancer deaths.
New research presented at ACR Convergence, the American College Rheumatology’s annual meeting, reveals that romosozumab, an osteoporosis drug, produces substantial gains in bone mineral density in the hip and lumbar spine within one year, and that transitioning patients to a potent antiresorptive drug can lead to even more bone density gains.
A new study shows that patients with rheumatic diseases across Africa, Southeast Asia, the Americas and Europe had trouble filling their prescriptions of antimalarial drugs during the 2020 global coronavirus pandemic, when antimalarials were touted as a possible COVID-19 treatment. Patients who could not access their antimalarial drugs faced worse physical and mental health outcomes as a result. Details of the research was presented at ACR Convergence, the American College of Rheumatology’s annual meeting.
New research presented at ACR Convergence, the American College Rheumatology’s annual meeting, showed that patients with rheumatic diseases whose infliximab treatment was individually assessed and adjusted with a new strategy called therapeutic drug monitoring did not achieve remission at higher rates compared to those who received standard care.
New research presented at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that tuberculosis (TB) screening and ongoing clinical care is needed for people on methotrexate who live in areas where the highly infectious illness is common. Methotrexate users who also take corticosteroids or other immunosuppressant therapies are at particular risk and need adequate TB screening.
New research shows that adults with lupus who take hydroxychloroquine do not have any differences in their corrected QT (QTc) intervals even if they have chronic kidney disease. The study was presented at ACR Convergence, the American College Rheumatology’s annual meeting.
A new study reveals that Black patients with rheumatoid arthritis were less likely to be prescribed a biologic treatment and more likely to use glucocorticoids, which carry a risk of serious long-term side effects. This study highlights ongoing racial disparities in the care of patients with rheumatic disease. Details of the study was shared at ACR Convergence, the American College of Rheumatology’s annual meeting.
New research presented at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that use of warfarin, a vitamin K drug widely prescribed to prevent blood clots, is associated with a significantly greater risk of knee and hip replacements in patients with osteoarthritis.
A new study presented at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that after three months of treatment with oral methotrexate, adults with primary knee osteoarthritis (OA) had significant improvements in physical function and inflammation, a sign that this inexpensive, generic pill may be an important intervention for knee OA.
New research shows that corticosteroid injections for knee OA treatment do not hasten a patient’s progression to a total knee replacement when compared with hyaluronic acid injections. Details of this study was presented at ACR Convergence, the American College of Rheumatology’s annual meeting.
New research shows that adults with systemic lupus erythematosus, who receive trimethoprim-sulfamethoxazole (TMP-SMX) are at high risk for adverse reactions to the drug, particularly if they are also positive for anti-Smith (anti-Sm) antibodies. Details of the study was presented at ACR Convergence, the American College of Rheumatology’s annual meeting.
New research presented at ACR Convergence, the American College of Rheumatology’s annual meeting, discovers that use of hydroxychloroquine does not cause any significant differences in QTc length or prolonged QTc in people with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE).
The American College of Rheumatology (ACR) will preview its 2020 Guideline for the Management of Rheumatoid Arthritis (RA) at ACR Convergence, the ACR’s annual meeting. The comprehensive, clinical recommendations for pharmacologic treatment of RA includes important updates to the previous guideline released in 2015.
A new approach to treating life-threatening snake bites responsible for around 100,000 deaths globally each year is being pioneered by an international research consortium led by University of Bristol scientists.
Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at The University of Texas MD Anderson Cancer Center have generated a valuable resource to aid in predicting drug sensitivity, to understand therapeutic resistance mechanisms and to identify optimal combination treatment strategies.
In a study of cancer patients treated with methylnaltrexone, about 50%–70% experienced relief from opioid-induced constipation within 4 hours without the use of additional treatments, compared with 15% of placebo-treated patients. In addition, more patients treated with methylnaltrexone maintained a response at 24 hours after dosing compared with patients treated with placebo.
In a small study of adults with major depression, Johns Hopkins Medicine researchers report that two doses of the psychedelic substance psilocybin, given with supportive psychotherapy, produced rapid and large reductions in depressive symptoms, with most participants showing improvement and half of study participants achieving remission through the four-week follow-up.
Inspired by a parasitic worm that digs its sharp teeth into its host’s intestines, Johns Hopkins researchers have designed tiny, star-shaped microdevices that can latch onto intestinal mucosa and release drugs into the body.
Beta-blockers could potentially be used to treat COVID-19, according to a new international study by Italian and Australian scientists.
FAU's Herbert Weissbach, Ph.D., recently received BioFlorida’s “Lifetime Achievement Award,” reserved to recognize outstanding leadership in the industry throughout an individual’s career and for significant contributions to industry growth.
Patients whose Type 2 diabetes is not controlled with metformin can benefit long-term from a two-drug combination treatment that also reduces weight.
Wistar scientists have designed and tested the first-of-its-kind synthetic DNA vaccine against Powassan virus (POWV), targeting portions of the virus envelope protein.
"Third spike" in COVID-19 cases, plus the vaccine trials: Live Expert Panel for October 29, 3PM EDT
A radioisotope researcher in the Radioisotope Science and Technology Division at the Department of Energy’s Oak Ridge National Laboratory, Davern is focusing on ways to use nanoparticles — particles 100 nanometers or smaller that can have special properties — to contain those radioisotopes and deliver them directly to cancer cells, where they can decay into different isotopes that irradiate those cells.
Researchers have found that a more intensive, less frequent drug regimen with currently available therapeutics could cure the infection that causes Chagas disease
Researchers from NUS Engineering have developed a novel conversion approach that marries chemical and biological processes to produce high-value amino acids such as L-DOPA and L-Proline from low-cost, abundant waste material like crustacean shells and sawdust.
In a review of evidence from the most reliable data from randomized trials to find likely small-to-moderate effects of remdesivir, researchers say that totality of evidence compiled before the WHO trial results justifies compassionate use of remdesivir for severely ill patients. A smaller trial in China showed significantly decreased mean recovery time but no suggestion of a mortality benefit. ACTT-1 found the same mean recovery time and a suggestion of a mortality benefit that did not achieve statistical significance.
Michigan State University Foundation Professor Guowei Wei wasn’t preparing machine learning techniques for a global health crisis. Still, when one broke out, he and his team were ready to help.
Dr. Edward Jones-Lopez, joins a Newswise Live Expert Panel on Thursday Oct. 29, from 3-4 PM EDT to discuss the AstraZenea COVID-19 vaccine trial.
Nationalistic behaviour by governments may exclude some countries from gaining access to COVID-19 vaccines and cost the global economy up to $1.2 trillion a year in GDP, according to a new study from the not-for-profit research organisation RAND Europe.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right